LAVA Therapeutics NV (FRA:4PKB)
€ 1.42 -0.04 (-2.74%) Market Cap: 39.35 Mil Enterprise Value: -32.91 Mil PE Ratio: 0 PB Ratio: 1.03 GF Score: 50/100

LAVA Therapeutics NV at Jefferies London Healthcare Conference Transcript

Nov 17, 2022 / 08:00AM GMT
Release Date Price: €4.76 (+8.18%)
Unidentified Analyst

Excellent. Welcome, everyone, to the final days of the Jefferies London Healthcare Conference. I hope it's been an incredibly productive conference for you all, and you have a productive last day. Today, it's my pleasure to invite LAVA Therapeutics to a fireside chat. I'd like to introduce the CEO, Steve Hurly; and CMO, Benjamin Winograd.

Gentlemen, how are you doing today?

Steve Hurly
LAVA Therapeutics N.V. - President & CEO

Doing really well. Appreciate you, guys, having us.

Benjamin Winograd
LAVA Therapeutics N.V. - Chief Medical Officer

Great. Thanks.

Questions & Answers

Unidentified Analyst

Excellent. And so just get kicked off, I was curious what is a gamma delta bispecific T cell engager? It's quite a mouthful.

Steve Hurly
LAVA Therapeutics N.V. - President & CEO

Yeah. It's a practice makes perfect one pronunciation, enunciation. So we at LAVA, our foundation technology is bispecifics to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot